Type II Diabetes

Publishing Date : June, 2015
Report Code : HCMD101
Price:
Single license $3,600
Site license $5,400
Global license $7,200


Type 2 Diabetes (T2D) Pipeline Analysis gives comprehensive insight on the various drugs being developed for the treatment of T2D. The report covers all the drugs being developed in various phases (Discovery, Preclinical, Clinical & Marketing). The pipeline focuses on novel pharmacologic drugs & regenerative medicines covering small molecules, monoclonal antibodies, stem cell therapies, Gene therapies, Recombinant proteins and RNA-based therapeutics, but excludes symptom relief drugs, generic combinations. The report also covers some of the hot targets in research for T2D treatments and disease progression biomarkers.

This report enables Pharmaceutical /Biotech companies, Academic institutes, Individual researchers, Investors, Medical technology companies, Service providers and other associated stake holders to identify and analyze the available licensing/collaborative commercial opportunities in the Type 2 Diabetes (T2D) Drug market. The report also provide strategic insights on medicines that are likely to have an impact on T2D treatment space and potentially alter standards of care in T2D in the foreseeable future. 

  • 1     REPORT DESCRIPTION
  • 2     INTRODUCTION
    • 2.1     Causes & Symptoms
    • 2.2     Diagnosis
    • 2.3     Unmet needs
    • 2.4     Epidemiology
    • 2.5     Current therapies
  • 3     HOT TARGETS, MECHANISMS & THERAPIES
    • 3.1     Novel Disease mechanisms & therapies
    • 3.2     Leading & hot targets of T2DM
    • 3.3     Novel targets of Diabetes
    • 3.4     T2D disease progression biomarkers
  • 4     MARKET DATA
    • 4.1     Forecasting model
    • 4.2     Market dynamics
    • 4.3     Market sizing
    • 4.4     Cost burden
  • 5     PIPELINE ANALYSIS
    • 5.1     Development stage
    • 5.2     Leading players
    • 5.3     Therapeutic segmentation
    • 5.4     Innovative approaches
    • 5.5     Target analysis
  • 6     SMALL MOLECULES
    • 6.1     Pipeline
    • 6.2     Competitive Analysis
  • 7     LARGE MOLECULE
    • 7.1     Pipeline
    • 7.2     Competitive Analysis
  • 8     MONOCLONAL ABs
    • 8.1     Pipeline
    • 8.2     Competitive Analysis
  • 9     STEMCELL THERAPY
    • 9.1     Pipeline
    • 9.2     Competitive Analysis
  • 10     RNA-BASED THERAPY
    • 10.1     Pipeline
    • 10.2     Competitive Analysis
  • 11     GENE THERAPY
    • 11.1     Pipeline
    • 11.2     Competitive Analysis
  • 12     RECOMBINANT FUSION PROTEINS
    • 12.1     Pipeline
    • 12.2     Competitive Analysis
  • 13     DRUG ANALYSIS BASED ON MECHANISM
  • 14     MAJOR PLAYERS
    • 14.1     Company Profiles
    • 14.2     Overview, Pipeline & Deals
  • 15     REFERENCES